Ipamorelin research guide
Pentapeptide growth-hormone secretagogue receptor agonist
A guide to Ipamorelin's early pharmacology and human PK/PD work, with clear separation from CJC-1295 and from performance claims.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
Ipamorelin is a synthetic pentapeptide and growth-hormone secretagogue receptor agonist. It is mechanistically distinct from GHRH analogues such as CJC-1295, even though the two names often appear together in catalogue blends. A blend record should verify both components rather than treating the combination as a single compound.
02 · Evidence position
What the literature can support
The indexed human literature includes a small dose-escalation pharmacokinetic/pharmacodynamic study in healthy volunteers. That shows a measurable experimental hormone response under controlled conditions; it does not establish broad performance, recovery or body-composition outcomes.
03 · Study-level map
Evidence and its limits
What human pharmacology has been measured?
A dose-escalation study measured Ipamorelin concentrations and growth-hormone responses in healthy male volunteers.
Limit: The study was designed for PK/PD modelling, not long-term clinical outcomes, and cannot validate an independent batch.
Why is it described as selective?
Earlier pharmacology compared secretagogue effects across in-vitro and animal systems and reported relative hormone selectivity.
Limit: Preclinical selectivity does not prove long-term human safety or a performance benefit.
04 · Analytical context
Questions a batch record should answer
- 01Does mass spectrometry confirm the declared pentapeptide and relevant stereochemistry-compatible identity?
- 02In a CJC-1295 blend, are both components resolved and quantified rather than represented by a single peak area?
- 03Are peptide content, counter-ion and moisture accounted for in the reported amount?
05 · Boundary conditions
What this record does not establish
- Short PK/PD studies do not establish long-term clinical benefit or safety.
- Ipamorelin and CJC-1295 act through different receptor systems and should not be conflated.
- No performance or administration recommendation is provided.
Sources checked
- 1.Pharmacokinetic-pharmacodynamic modelling of Ipamorelin in human volunteers
PubMed / Pharmaceutical Research · 1999 · Primary study
- 2.Ipamorelin, the first selective growth hormone secretagogue
PubMed / European Journal of Endocrinology · 1998 · Primary study